ESR1 and breast carcinoma: The Chemotherapy Adjuvant Study for women with advanced Age (CASA) trial studied elderly women aged ≥65 years with endocrine non-responsive (ER and PR negative) breast cancer who were not suitable to receive standard chemotherapy regimen [42].